Clobetasol Propionate


Micro Labs Limited
Human Prescription Drug
NDC 42571-362
Clobetasol Propionate is a human prescription drug labeled by 'Micro Labs Limited'. National Drug Code (NDC) number for Clobetasol Propionate is 42571-362. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Clobetasol Propionate drug includes Clobetasol Propionate - .5 mg/mL . The currest status of Clobetasol Propionate drug is Active.

Drug Information:

Drug NDC: 42571-362
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Clobetasol Propionate
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Clobetasol Propionate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Micro Labs Limited
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CLOBETASOL PROPIONATE - .5 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 02 Oct, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 31 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA211494
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Micro Labs Limited
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:861487
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0342571362997
0342571362812
UPC stands for Universal Product Code.
UNII:779619577M
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Corticosteroid Hormone Receptor Agonists [MoA]
Corticosteroid [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
42571-362-811 BOTTLE in 1 CARTON (42571-362-81) / 25 mL in 1 BOTTLE02 Oct, 2019N/ANo
42571-362-991 BOTTLE in 1 CARTON (42571-362-99) / 50 mL in 1 BOTTLE02 Oct, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Clobetasol propionate clobetasol propionate clobetasol propionate clobetasol carbomer homopolymer type b (allyl pentaerythritol crosslinked) isopropyl alcohol sodium hydroxide water

Indications and Usage:

Indications and usage clobetasol propionate topical solution, usp is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 ml/week because of the potential for the drug to suppress the hpa axis. this product is not recommended for use in pediatric patients under 12 years of age.

Dosage and Administration:

Dosage and administration clobetasol propionate topical solution should be applied to the affected scalp areas twice daily, once in the morning and once at night. clobetasol propionate topical solution is potent; therefore, treatment must be limited to 2 consecutive weeks and amounts greater than 50 ml/week should not be used. clobetasol propionate topical solution is not to be used with occlusive dressings. geriatric use in studies where geriatric patients (65 years of age or older, see precautions ) have been treated with clobetasol propionate topical solution, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.

Contraindications:

Contraindications clobetasol propionate topical solution is contraindicated in patients with primary infections of the scalp, or in patients who are hypersensitive to clobetasol propionate, other corticosteroids, or any ingredient in this preparation.

Adverse Reactions:

Adverse reactions clobetasol propionate topical solution is generally well tolerated when used for 2-week treatment periods. the most frequent adverse events reported for clobetasol propionate topical solution have been local and have included burning and/or stinging sensation, which occurred in 29 of 294 patients; scalp pustules, which occurred in 3 of 294 patients; and tingling and folliculitis, each of which occurred in 2 of 294 patients. less frequent adverse events were itching and tightness of the scalp, dermatitis, tenderness, headache, hair loss, and eye irritation, each of which occurred in 1 of 294 patients. the following local adverse reactions are reported infrequently when topical corticosteroids are used as recommended. these reactions are listed in an approximately decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the s
kin, secondary infection, skin atrophy, striae, and miliaria. systemic absorption of topical corticosteroids has produced reversible hpa axis suppression, manifestations of cushing's syndrome, hyperglycemia, and glucosuria in some patients. in rare instances, treatment (or withdrawal of treatment) of psoriasis with corticosteroids is thought to have exacerbated the disease or provoked the pustular form of the disease, so careful patient supervision is recommended. to report suspected adverse reactions, contact saptalis pharmaceuticals, llc at 1-833-727-8254 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Overdosage:

Overdosage topically applied clobetasol propionate can be absorbed in sufficient amounts to produce systemic effects (see precautions ).

Description:

Description clobetasol propionate topical solution, usp contains the active compound clobetasol propionate, usp a synthetic corticosteroid, for topical dermatologic use. clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. chemically, clobetasol propionate, usp is (11β,16β)-21-chloro-9‑fluoro‑11‑hydroxy‑16‑methyl‑17‑(1‑oxo-­propoxy) pregna-1,4-diene-3,20-dione, and it has the following structural formula: clobetasol propionate, usp has the molecular formula c 25 h 32 clfo 5 and a molecular weight of 466.97. it is a white to cream-colored crystalline powder, soluble in acetone, in dimethyl sulfoxide, in chloroform, in methanol, and in dioxane. sparingly soluble in ethanol; slightly soluble in benzene and diethyl ether; practically insoluble in water. clobetasol propionate topical solution, usp contains clobetasol propionate, usp 0.5 mg/g in a base of carbomer 974p, isopropyl alcohol (40% w/w), purified water, and sodium hydroxide. clobetasol-structure

Clinical Pharmacology:

Clinical pharmacology the corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. in pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects. topical corticosteroids such as clobetasol propionate are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions. however, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. clobetasol propionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs. pharmacokinetics the extent of percutaneous absorption of topical corticosteroids, including clobetasol propionate, is determined by many factors, including t
he vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings (see dosage and administration ). as with all topical corticosteroids, clobetasol propionate can be absorbed from normal intact skin. inflammation and/or other disease processes in the skin may increase percutaneous absorption. occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see dosage and administration ). once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similarly to systemically administered corticosteroids. corticosteroids are bound to plasma proteins in varying degrees. corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. some of the topical corticosteroids, including clobetasol propionate and its metabolites, are also excreted into the bile. following repeated nonocclusive application in the treatment of scalp psoriasis, there is some evidence that clobetasol propionate topical solution has the potential to depress plasma cortisol levels in some patients. however, hypothalamic-pituitary-adrenal (hpa) axis effects produced by systemically absorbed clobetasol propionate have been shown to be transient and reversible upon completion of a 2-week course of treatment.

How Supplied:

How supplied clobetasol propionate topical solution, usp 0.05% is a clear, colorless liquid supplied in plastic squeeze bottles, 25 ml (ndc 42571-362-81) and 50 ml (ndc 42571-362-99). store at 20° to 25°c (68° to 77°f), with excursions permitted between 15° to 30°c (59° to 86°f) [see usp controlled room temperature]. do not refrigerate. keep tightly closed. do not use near an open flame. distributed by: micro labs usa, inc. somerset, nj 08873 manufactured by: saptalis pharmaceuticals, llc hauppauge, ny 11788 revised: january 2022-r2

Package Label Principal Display Panel:

Package/label display panel - 25 ml label ndc 42571-362-81 clobetasol propionate topical solution, usp 0.05% scalp application for dermatologic use only– not for ophthalmic use. rx only 25 ml clobetasol-label1

Package/label display panel - 25 ml carton ndc 42571-362-81 clobetasol propionate topical solution, usp 0.05% scalp application for dermatologic use only– not for ophthalmic use. rx only 25 ml clobetasol-carton1

Package/label display panel - 50 ml label ndc 42571-362-99 clobetasol propionate topical solution, usp 0.05% scalp application for dermatologic use only– not for ophthalmic use. rx only 50 ml clobetasol-label2

Package/label display panel - 50 ml carton ndc 42571-362-99 clobetasol propionate topical solution, usp 0.05% scalp application for dermatologic use only– not for ophthalmic use. rx only 50 ml clobetasol-carton2


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.